N Zealand ditches MSD's Lipex for generic
This article was originally published in Scrip
Executive Summary
The New Zealand drug agency, Pharmac, which decides which medicines will be funded by the state, will not be subsidising Merck Sharp & Dohme's cholesterol treatment, Lipex (simvastatin), opting for the generic supplier Arrow-Simva instead.